132 related articles for article (PubMed ID: 37036487)
1. Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer.
Nihei S; Ikeda T; Aoki T; Murasato F; Yaegashi M; Asahi K; Kudo K
Cancer Chemother Pharmacol; 2023 May; 91(5):427-434. PubMed ID: 37036487
[TBL] [Abstract][Full Text] [Related]
2. Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab.
Yu Z; Xu H; Feng M; Chen L
Cancer Chemother Pharmacol; 2024 Jun; 93(6):587-593. PubMed ID: 38402561
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab.
Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Kondo N; Matsubara T; Yanagita M; Matsumoto S; Muto M
Clin J Gastroenterol; 2020 Jun; 13(3):316-319. PubMed ID: 31707696
[TBL] [Abstract][Full Text] [Related]
4. Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies.
Lee CS; Alwan LM; Sun X; McLean KA; Urban RR
J Oncol Pharm Pract; 2016 Dec; 22(6):771-776. PubMed ID: 26447100
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer.
Moisuc DC; Marinca MV; Gafton B; Alexa-Stratulat T; Pavel-Tanasa M; Cianga P
Curr Oncol; 2022 May; 29(6):3996-4011. PubMed ID: 35735428
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment.
Fukuda S; Niisato Y; Tsuji M; Fukuda S; Hagiwara Y; Onoda T; Suzuki H; Tange Y; Yamada T; Yamamoto Y; Moriwaki T
Anticancer Res; 2023 May; 43(5):2085-2090. PubMed ID: 37097650
[TBL] [Abstract][Full Text] [Related]
8. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Losa F; Bosch C; Escudero P; Casado E; Jorge M; Bohn U; Pérez-Carrión R; Carmona A; Custodio AB; Maurel J
PLoS One; 2015; 10(1):e0116527. PubMed ID: 25602286
[TBL] [Abstract][Full Text] [Related]
9. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer.
Iwasa S; Nakajima TE; Nagashima K; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2013 Jan; 33(1):309-16. PubMed ID: 23267162
[TBL] [Abstract][Full Text] [Related]
10. Assessment of extended urine protein monitoring frequency in patients receiving bevacizumab.
Schiffer M; Zukovic L; Hall S; Merl MY
J Oncol Pharm Pract; 2021 Jun; 27(4):902-906. PubMed ID: 32715917
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study.
Lim AR; Kim JH; Hyun MH; Kim YH; Lee S
Support Care Cancer; 2022 Oct; 30(10):8129-8137. PubMed ID: 35779133
[TBL] [Abstract][Full Text] [Related]
12. Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy.
Crucitta S; Restante G; Del Re M; Bertolini I; Bona E; Rofi E; Fontanelli L; Gianfilippo G; Fogli S; Stasi I; Ghilli M; Fontana A; Danesi R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1219-1227. PubMed ID: 31529205
[TBL] [Abstract][Full Text] [Related]
13. Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study.
Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Sakuragi M; Uchino E; Hiragi S; Yamamoto S; Sakai K; Matsubara T; Yanagita M; Muto M
Int J Clin Oncol; 2024 Apr; 29(4):398-406. PubMed ID: 38351273
[TBL] [Abstract][Full Text] [Related]
14. Proteinuria with first-line therapy of metastatic renal cell cancer.
Land JD; Chen AH; Atkinson BJ; Cauley DH; Tannir NM
J Oncol Pharm Pract; 2016 Apr; 22(2):235-41. PubMed ID: 25505255
[TBL] [Abstract][Full Text] [Related]
15. Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.
Shah SR; Gressett Ussery SM; Dowell JE; Marley E; Liticker J; Arriaga Y; Verma U
Ann Oncol; 2013 Apr; 24(4):960-5. PubMed ID: 23175623
[TBL] [Abstract][Full Text] [Related]
16. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
Lafayette RA; McCall B; Li N; Chu L; Werner P; Das A; Glassock R
Am J Nephrol; 2014; 40(1):75-83. PubMed ID: 25059491
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
Quintanilha JCF; Wang J; Sibley AB; Jiang C; Etheridge AS; Shen F; Jiang G; Mulkey F; Patel JN; Hertz DL; Dees EC; McLeod HL; Bertagnolli M; Rugo H; Kindler HL; Kelly WK; Ratain MJ; Kroetz DL; Owzar K; Schneider BP; Lin D; Innocenti F
Br J Cancer; 2022 Feb; 126(2):265-274. PubMed ID: 34616010
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1 in the kidney and urine of patients with glomerular disease and proteinuria.
Vlachojannis JG; Tsakas S; Petropoulou C; Goumenos DS; Alexandri S
Clin Nephrol; 2002 Nov; 58(5):337-43. PubMed ID: 12425483
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: A meta-analysis.
Chen X; Chen Y; Cai X; Zhang D; Fan L; Qiu H; Zhang B; Guo G
J Cancer Res Ther; 2017; 13(5):869-877. PubMed ID: 29237919
[TBL] [Abstract][Full Text] [Related]
20. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats.
Brochu E; Lacasse S; Moreau C; Lebel M; Kingma I; Grose JH; Larivière R
Nephrol Dial Transplant; 1999 Aug; 14(8):1881-8. PubMed ID: 10462266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
